Stay updated on AstraZeneca PLC ADR Press Releases

Sign up to get notified when there's something new on the AstraZeneca PLC ADR Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the AstraZeneca PLC ADR Press Releases page

  1. Check
    6 days ago
    Change Detected
    Summary
    New press releases have been added highlighting regulatory approvals and major presentations (Datroway US approval as a first-in-class TROP2 ADC; EU CHMP recommendations for Enhertu and Camizestrant; ASCO 2026 data showcase; Baxfendy US approval), while older entries from Q1 and several April 2026 releases have been removed from the listing.
    Difference
    5%
    Check dated 2026-05-24T14:25:16.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    Three new press releases were added to the Latest feed with dates 15 May 2026, 14 May 2026 and 12 May 2026, expanding the page with the most recent company announcements. Three older releases dated 10 Apr 2026, 02 Apr 2026 and 31 Mar 2026 were removed from the feed.
    Difference
    5%
    Check dated 2026-05-17T09:19:50.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    New social media icons for Twitter and LinkedIn were added to the header, providing quick access to AstraZeneca's social channels from the Press Releases page.
    Difference
    2%
    Check dated 2026-05-10T09:21:54.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Five new press releases were added to the list: Truqap recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer (30 April 2026); Update on FDA Advisory Committee vote on camizestrant in combination with a CDK4/6 inhibitor for advanced HR-positive breast cancer (30 April 2026); Q1 2026 results (29 April 2026); Breztri approved in the US for asthma as first and only triple therapy for patients 12 years of age and older (28 April 2026); and Saphnelo approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus (27 April 2026). Additionally, older press releases were removed from the archive.
    Difference
    5%
    Check dated 2026-05-03T03:18:00.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    New recent press release entries were added to the press releases list, including items dated 21 April 2026 and 20 April 2026. Two earlier press release items were removed, including one dated 10 February 2026 and another dated 03 February 2026.
    Difference
    5%
    Check dated 2026-04-25T18:51:09.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    Added a new press release entry for 10 April 2026 about Alexion data at the 2026 AAN Annual Meeting. Removed the 03 February 2026 update on Saphnelo subcutaneous administration in systemic lupus erythematosus.
    Difference
    0.9%
    Check dated 2026-04-11T10:44:51.000Z thumbnail image

Stay in the know with updates to AstraZeneca PLC ADR Press Releases

Enter your email address, and we'll notify you when there's something new on the AstraZeneca PLC ADR Press Releases page.